eftilagimod alpha,pembrolizumab
Immutep,Merck
['increase,(-increased)', 'eftilagimod', 'ease,(-please),(-disease),(-incrrease),(-decrease)', 'immutep']
immutep announces compelling clinical results from phase ii trial utilizing its first-in-class soluble lag-3 protein, eftilagimod alpha, in 1st line nsclc at sitc 2022 annual meeting - release overall response rate (orr) increases to 40.4%, according t... 